Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
GROWTH
KesimptaⓇ continues strong launch trajectory doubling sales vs. PY
Kesimpta
Sales evolution
USD m, % cc
Ex-US
US
US NBRx1
Rolling 4 weeks
350
300
+105%
250
489
116
200
150
239
100
373
204
60
50
0
Q2 2022
Q2 2023
Sept 2020
June 2023
Global sales
US: Growing faster than market1,2
TRX +80% YTD vs. PY (market flat)
NBRX +43% vs. PY (market +1%)
B-cell NBRX share -54% of MS market
Europe: Strong launch momentum³
>24k patients treated, thereof >1/3 naive patients
Confident in future growth
Significant room to grow
About a third of patients with MS on B-Cell therapy 1,2
Compelling product profile
1 minute a month dosing from home/anywhere³;
5-year efficacy and safety data 5,6
See last page for references.
TRX total prescriptions. NBRX-new to brand prescription. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report.
11 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation